Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts.
暂无分享,去创建一个
J. Eisman | G. Thomas | J A Eisman | G P Thomas | S U Baker | E M Gardiner | E. Gardiner | E. Gardiner | G. P. Thomas | S. Baker
[1] T. Martin,et al. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity , 1994, Journal of cellular biochemistry.
[2] J. Aubin,et al. Characterization of the 1,25-(OH)2D3-induced inhibition of bone nodule formation in long-term cultures of fetal rat calvaria cells. , 1993, Endocrinology.
[3] N. Kurihara,et al. Effect of 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity and collagen synthesis in osteoblastic cells, clone MC3T3-E1. , 1984, Biochemical and biophysical research communications.
[4] H. Sussman,et al. Characterization of a human osteoblastic osteosarcoma cell line (SAOS‐2) with high bone alkaline phosphatase activity , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] K. Abromeit. Music Received , 2023, Notes.
[6] D. Lacey,et al. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.
[7] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[8] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[9] E. Ogata,et al. Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. , 1991, Bone.
[10] W. Otto,et al. Fluorimetric DNA assay for cell growth estimation. , 1992, Analytical biochemistry.
[11] S. K. Lee,et al. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. , 1999, Endocrinology.
[12] Allan Bradley,et al. Increased bone formation in osteocalcin-deficient mice , 1996, Nature.
[13] O. H. Lowry,et al. The quantitative histochemistry of brain. II. Enzyme measurements. , 1954, The Journal of biological chemistry.
[14] D. V. Cohn,et al. Target cells in bone for parathormone and calcitonin are different: enrichment for each cell type by sequential digestion of mouse calvaria and selective adhesion to polymeric surfaces. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[15] S. Mochizuki,et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.
[16] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[17] N. Udagawa,et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.
[18] S. Kaesler,et al. 1,25 Dihydroxyvitamin-D3 Attenuates the Confluence-Dependent Differences in the Osteoblast Characteristic Proteins Alkaline Phosphatase, Procollagen I Peptide, and Osteocalcin , 1999, Calcified Tissue International.
[19] P. Robey,et al. Human bone cells in vitro. , 1985, Calcified tissue international.
[20] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[21] E. Jimi,et al. Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. , 1997, Methods in enzymology.
[22] A. Flanagan,et al. The role of 1,25-dihydroxycholecalciferol and prostaglandin E2 in the regulation of human osteoclastic bone resorption in vitro. , 1995, International journal of experimental pathology.
[23] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] T. Martin,et al. Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .
[25] J. Eisman,et al. Human and murine osteocalcin gene expression: conserved tissue restricted expression and divergent responses to 1,25-dihydroxyvitamin D3 in vivo. , 1997, Molecular endocrinology.
[26] N. Nagata,et al. Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells , 1998 .
[27] Brian R. Wong,et al. TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.
[28] N. Sato,et al. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. , 1999, Biochemical and biophysical research communications.
[29] T. Martin,et al. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.
[30] S. Reddy,et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. , 2000, The Journal of clinical investigation.
[31] Y. Yoshimura,et al. Effect of extracellular calcium concentrations on osteoclast differentiation in vitro. , 1999, Biochemical and biophysical research communications.
[32] T. Spelsberg,et al. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] J. Eisman,et al. Species-divergent regulation of human and mouse osteocalcin genes by calciotropic hormones. , 2000, Experimental cell research.
[34] R. Kesterson,et al. Analysis of Osteocalcin Expression in Transgenic Mice Reveals a Species Difference in Vitamin D Regulation of Mouse and Human Osteocalcin Genes , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] K Yano,et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.
[36] N. Kurihara,et al. Effect of 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity and collagen synthesis in osteoblastic cells, clone MC3T3-El1 , 1984 .
[37] G. Stein,et al. Progressive development of the rat osteoblast phenotype in vitro: Reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix , 1990, Journal of cellular physiology.
[38] D. Lacey,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in , 2022 .
[39] N. Udagawa,et al. A novel molecular mechanism modulating osteoclast differentiation and function. , 1999, Bone.
[40] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[41] C. Gundberg,et al. Development and validation of a radioimmunoassay for mouse osteocalcin: paradoxical response in the Hyp mouse. , 1992, Endocrinology.
[42] Yongwon Choi,et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[43] Y. Deyama,et al. Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells. , 2000, Biochemical and biophysical research communications.
[44] P. Härkönen,et al. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. , 1998, Bone.
[45] T. Katagiri,et al. Subcloning of three osteoblastic cell lines with distinct differentiation phenotypes from the mouse osteoblastic cell line KS-4. , 1996, Bone.
[46] C. Devlin,et al. The effects of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation of human marrow stromal cells in vitro. , 1994, Archives of oral biology.
[47] W. Wilfinger,et al. Fluorometric quantification of DNA in cells and tissue. , 1983, Analytical biochemistry.
[48] G S Stein,et al. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. , 1993, Endocrine reviews.
[49] T. Martin,et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.
[50] B. Frenkel,et al. Species-specific glucocorticoid and 1,25-dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. , 1997, Endocrinology.
[51] Y. Deyama,et al. Low calcium environment effects osteoprotegerin ligand/osteoclast differentiation factor. , 2000, Biochemical and biophysical research communications.
[52] Rui Zhang,et al. 1,25-Dihydroxyvitamin D3 Inhibits Osteocalcin Expression in Mouse through an Indirect Mechanism* , 1997, The Journal of Biological Chemistry.